Cosmos Health Adds 2.5M Units to Orderbook, Total Surpasses 27.5M
COSM sits 69% above its 52-week low of $0.162.
Summary
Cana Laboratories, a Cosmos Health subsidiary, signed a five-year contract manufacturing agreement with Viofar for 2.5 million units of ROSARTIA, a rosuvastatin cardiovascular drug. This adds roughly 500,000 units annually and lifts Cana's cumulative orderbook to over 27.5 million units, up from over 25 million in June. The deal expands Cana's presence in cardiovascular pharmaceuticals and provides multi-year revenue visibility. The orderbook growth supports higher utilization of the company's 54,000-square-foot GMP-certified facility in Athens. Investors will watch for further orderbook expansion and the impact on recurring cash flows.
At the time of this announcement, COSM was trading at $0.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $0.16 to $1.32. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.